Voclosporin: newer analyses of a randomized, controlled trial for noninfectious uveitis
Acta Ophthalmologica, 08/21/2012
Bodaghi B et al. – In Study LX211–01, clinically meaningful reduction in vitreous haze with strong statistical significance was observed. The response to treatment with voclosporin was early and sustained. In Study LX211–02, there was an up to 50% reduction vs. control in inflammatory exacerbation recurrence rate. Voclosporin safety is consistent with the class and is manageable with routine monitoring.